Figure 2.

Chemoadjuvant effect of NC13 or Vms on the cellular survival of MDA-MB-231 and MCF7 cells. (A,C) MDA-MB-231 and MCF7 cells were treated with increasing concentrations of either NC13 or Vms for 48 h. (B,D) The cells were treated with either NC13 (5 µg/mL) or Vms (10 µM) in the presence of cisplatin. After 2 days, the MTT assay was performed to assess cellular viability. Rosiglitazone (Rosi, 20 μM) was used as a positive control. All data are presented as mean ± SEM. Statistical significance was evaluated by one-way ANOVA, followed by post hoc tukey’s multiple comparison test. ^*P < 0.05, ^**P < 0.01.